Sermorelin

A synthetic 29-residue C-terminally amidated peptide corresponding to the N-terminal fragment of a 44-residue hypothalamic peptide.

Molecular Profile

Type
Synthetic peptide (29 residues, C-terminal amide)
Molecular formula
C149H246N44O42S
Molecular weight
~3,358 g/mol
CAS number
86168-78-7
Amino acids
29
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Modification
C-terminal amidation; sequence corresponds to residues 1-29 of human GHRH (the N-terminal fragment that retains intrinsic activity).

Mechanism & Target Class

A synthetic 29-residue C-terminally amidated peptide corresponding to the N-terminal fragment (residues 1-29) of a 44-residue hypothalamic peptide - the minimal segment that retains the intrinsic structural activity of the longer parent. Solution NMR in a membrane-mimetic solvent describes substantial alpha-helical character, and cryo-EM of the peptide bound to its class B1 (secretin-like) G-protein-coupled receptor complex resolves a continuous alpha-helical conformation contacting the receptor extracellular domain, extracellular loops, and transmembrane helices. Binding is described by a two-domain ('two-step') model in which the peptide engages both the receptor extracellular domain and its transmembrane core. As a small unmodified peptide it carries a single oxidation-sensitive methionine and is characterized by rapid circulatory clearance, distinguishing it from chemically stabilized analogs bearing acyl or amino-acid-substitution modifications.

Storage & Handling

Lyophilized
-20°C (-80°C long term); powder protected from light, typically stable many months desiccated.
Handling
Avoid freeze-thaw; aliquot; protect from light and moisture. Contains an oxidation-sensitive methionine.

Primary Database

PubChem CID 16132413 ↗

References (20)

  1. Reviews

    1

    Granata R, et al. (2025). Nat Rev Endocrinol

    DOI: 10.1038/s41574-024-01052-1PubMed 39537825

  2. 2

    Montero-Hidalgo AJ, et al. (2025). Rev Endocr Metab Disord

    DOI: 10.1007/s11154-025-09943-yPubMed 39838154

  3. 3

    Walker RF. (2006). Clin Interv Aging

    DOI: 10.2147/ciia.2006.1.4.307PubMed 18046908

  4. 4

    Lin-Su K, Wajnrajch MP. (2002). Rev Endocr Metab Disord

    DOI: 10.1023/A:1020949507265

  5. 5

    Prakash A, Goa KL. (1999). BioDrugs

    DOI: 10.2165/00063030-199912020-00007PubMed 18031173

  6. Clinical

    6

    Baker LD, et al. (2012). Arch Neurol

    PubMed 22869065

  7. 7

    Khorram O, et al. (1997). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.82.5.3943PubMed 9141536

  8. 8

    Vittone J, et al. (1997). Metabolism

    DOI: 10.1016/s0026-0495(97)90174-8PubMed 9005976

  9. 9

    Thorner M, et al. (1996). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.81.3.8772599PubMed 8772599

  10. 10

    Corpas E, et al. (1992). J Clin Endocrinol Metab

    DOI: 10.1210/jcem.75.2.1379256PubMed 1379256

  11. 11

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT03018886

  12. Primary research

    12

    Zhou F, et al. (2020). Nat Commun

    DOI: 10.1038/s41467-020-18945-0PubMed 33060564

  13. 13

    Kanashiro-Takeuchi RM, et al. (2012). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.1119203109PubMed 22203988

  14. 14

    Kanashiro-Takeuchi RM, et al. (2010). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.0914138107

  15. 15

    Godfrey P, et al. (1993). Nat Genet

    DOI: 10.1038/ng0793-227

  16. 16

    Mayo KE. (1992). Mol Endocrinol

    DOI: 10.1210/mend.6.10.1333056PubMed 1333056

  17. 17

    Theriault Y, et al. (1988). Biopolymers

    DOI: 10.1002/bip.360271204

  18. 18

    Ling N, et al. (1984). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.81.14.4302PubMed 6431406

  19. 19

    Rivier J, et al. (1982). Nature

    DOI: 10.1038/300276a0

  20. 20

    Guillemin R, et al. (1982). Science

    DOI: 10.1126/science.6812220PubMed 6812220